0001179110-20-006718.txt : 20200529
0001179110-20-006718.hdr.sgml : 20200529
20200529164032
ACCESSION NUMBER: 0001179110-20-006718
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200528
FILED AS OF DATE: 20200529
DATE AS OF CHANGE: 20200529
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JANNEY DANIEL
CENTRAL INDEX KEY: 0001198325
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35986
FILM NUMBER: 20928619
MAIL ADDRESS:
STREET 1: ONE EMBARCADERO CENTER SUITE 3700
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Esperion Therapeutics, Inc.
CENTRAL INDEX KEY: 0001434868
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3891 RANCHERO DRIVE, SUITE 150
CITY: ANN ARBOR
STATE: MI
ZIP: 48108
BUSINESS PHONE: 734-887-3903
MAIL ADDRESS:
STREET 1: 3891 RANCHERO DRIVE, SUITE 150
CITY: ANN ARBOR
STATE: MI
ZIP: 48108
FORMER COMPANY:
FORMER CONFORMED NAME: HDL THERAPEUTICS INC
DATE OF NAME CHANGE: 20080513
4
1
edgar.xml
FORM 4 -
X0306
4
2020-05-28
0
0001434868
Esperion Therapeutics, Inc.
ESPR
0001198325
JANNEY DANIEL
C/O ESPERION THERAPEUTICS INC.
3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR
MI
48108
1
0
0
0
Common Stock
2020-05-28
4
A
0
6106
0.00
A
11073
D
Common Stock
2018-02-28
4
J
0
24565
0.00
A
24565
I
By Alta Bioequities, L.P.
The shares vest in full on the earlier of (i) May 28, 2021 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2020.
On February 28, 2018, Alta Partners VIII, L.P. ("APVIII") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13. Alta Bioequities, L.P. ("Alta Bioequities") received 24,565 of these shares. Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P.
The 24,565 shares of Common Stock reported in this column as indirectly beneficially owned by the Reporting Person through Alta Bioequities were previously reported by the Reporting Person as indirectly beneficially owned through APVIII. These shares became indirectly beneficially owned by the Reporting Person through Alta Bioequities as a result of a pro rata distribution of shares described in footnote (2).
/s/ Richard B. Bartram, by power of attorney
2020-05-29